Skip to main content

Advertisement

Table 1 Patient and transplant characteristics

From: Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT

  sCBT (n = 172) dCBT (n = 362) P valuea
Median patient age, months (range) 50 (18–68) 52 (18–76) 0.17
Median follow-up, months (range) 54 (1–118) 34 (2–98) <0.001
Year of transplantation, median (range) 2008 (2004–2014) 2010 (2005–2014) <0.001
Recipient sex M, no. (%) 71 (41) 201 (56) 0.002
Recipient weight, median (range) 64 70 <0.001
Time from diagnosis to CBT (months), median (range)
CR1 6 (3–70) 6 (2–147) 0. 7
CR2 22 (4–95) 22 (6–209) 0.7
Disease, no. (%)
Acute myeloid leukemia 131 (76) 277 (76) 0.9
Acute lymphoblastic leukemia 41 (24) 85 (24)  
Donor CMV seropositive, no. (%) 107 (65) 222 (64) 0.92
Status at transplantation, no. (%)
CR1 91 (53) 207 (57) 0.6
CR2 72 (42) 139 (38)  
CR3 9 (5) 16 (4)  
Cytogenetics, no. (%)    0.85
Acute myeloid leukemia
Good riskb 7 (5) 21 (8)  
Intermediate riskc 82 (62) 172 (62)  
High riskd 20 (15) 33 (12)  
Not reported/failed 22 (17) 51 (18)  
Acute lymphoblastic leukemia
Intermediate riske 15 (37) 31 (36)  
High riskf 18 (44) 38 (45)  
Not reported/failed 8 (19) 16 (19)  
Conditioning regimen, no. (%)    <0.001
TCF 113 (66) 300 (83)  
TBF 19 (11) 5 (1)  
TTBF 9 (5) 0  
FM+/−C 3 (2) 12 (3)  
CF+/−T 9 (5) 5 (1)  
Other 19 (11) 38 (10)  
Missing 0 2 (0.5)  
Recipient CMV-seronegative, no. (%) 57 (35) 123 (36) 0.9
ATG, no. (%) 61 (37) 51 (16) <0.001
Postgrafting immunosuppression, no. (%)
CNI + MMF 121 (70) 327 (90) <0.001
CNI + Pred 21 (12) 4 (1)  
CNI + Mtx 10 (6) 9 (2)  
CNI alone 10 (6) 11 (3)  
Other 10 (6) 11 (3)  
  1. M male; CR complete remission; no. number of patients; ATG anti-thymocyte globulins; TNC total nucleated cells; TCF total body irradiation (TBI), cyclophosphamide and fludarabine; TBF Thiotepa, busulfan, and fludarabine; TTBF TBI, Thiotepa, busulfan, and fludarabine; FM+/-C fludarbine, melphalan with or without cyclophosphamide; CF+/-T cyclophosphamide, fludarabine with or without thiothepa; CNI calcineurin inhibitor (cyclosporine A or tacrolimus); MMF mycophenolate mofetil; MTX methotrexate; Pred predisolone
  2. aCalculated with χ2 statistics for categorical variables and Mann-Whitney test for continuous variables
  3. bDefined as t(8;21), t(15;17), inv or del (16), or acute promyelocyticleukemia, these abnormalities only or combined with others
  4. cDefined as all cytogenetics not belonging to the good or high risk (including trisomias)
  5. dDefined as 11q23 abnormalities, complex caryotype, and abnormalities of chromosomes 5 and 7
  6. eDefined as t(9;22), t(4;11), t(8;14), t(14;18), low hypodiploidy (30–39 chromosomes)/near triploidy (60–78 chromosomes), and complex karyotype
  7. fAll others